Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fasenra Demonstrates Durability Over the Full 8-week Treatment Period

NCT07654842 is registered in ClinicalTrials.gov with Endeavor Health as lead sponsor.

NCT NCT07654842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07654842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fasenra Demonstrates Durability Over the Full 8-week Treatment Period
Lead sponsor
Endeavor Health
Phase
Phase 4
Overall status
Enrolling by invitation
Start date
July 1, 2026
Completion date
January 1, 2028
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma, eosinophilic asthma, severe asthma, severe eosinophilic asthma